Bruker Corporation filings document financial results, capital returns, governance actions and proxy matters for a scientific instruments and diagnostics company.
Recent Form 8-K disclosures cover quarterly and annual operating results, outlook commentary, segment information for Bruker Scientific Instruments and Bruker Energy & Supercon Technologies, and dividends on common stock and 6.375% Mandatory Convertible Preferred Stock, Series A. The definitive proxy statement covers board elections, executive compensation, pay-versus-performance data, shareholder voting items and governance practices. Other material-event filings record board composition changes and executive transition arrangements.
Bruker Corporation reported Q1 2026 revenue of $823.4 million, slightly higher than $801.4 million a year earlier, with growth in both product and service revenue. Gross profit was $379.8 million, but higher operating expenses and restructuring and impairment charges reduced operating income to $10.2 million from $31.8 million.
Net income attributable to Bruker was $14.4 million, but after $10.9 million of preferred dividends, net income to common shareholders was $3.5 million, or $0.02 per diluted share, down from $0.11. Operating cash flow improved to $71.2 million, while cash fell as Bruker repaid $181.3 million of long-term debt and invested in acquisitions.
Bruker completed the acquisition of the remaining 60% of Tofwerk, recognizing total consideration of $81.0 million and a $12.2 million non-taxable gain on remeasuring its prior stake. The company recorded $17.8 million of restructuring costs and $12.9 million of long-lived asset impairments, mainly in the BSI NANO and CALID segments, and continued a corporate-wide cost program expected to finish in 2026.
Bruker Corp ownership disclosure: FMR LLC reports beneficial ownership of 19,208,582.41 shares of Bruker common stock, representing 12.4% of the class. The filing states FMR LLC has sole dispositive power over 19,208,582.41 shares and sole voting power of 14,435,518.96 shares.
The schedule states that one or more other persons have rights to dividends or sale proceeds but no single other person holds more than 5% of the class. The filing is signed under a power of attorney and references Exhibit 99 and Exhibit 24 for related authority.
Bruker Corporation reported mixed first-quarter 2026 results while reaffirming its full-year outlook. Q1 2026 revenue was $823.4 million, up 2.7% year-over-year, but organic revenue declined 4.4% as US academic demand, tariffs, and currency effects weighed on results. GAAP diluted EPS fell to $0.02 from $0.11, and non-GAAP diluted EPS declined to $0.31 from $0.47.
Bruker Scientific Instruments delivered $759.8 million of revenue, up 2.1% with a 5.0% organic decline, while BEST revenue rose 12.8% to $66.9 million with 3.0% organic growth. Management highlighted high single-digit organic bookings growth for the BSI segment and a book-to-bill ratio above 1.0x for the third consecutive quarter.
The company reconfirmed its 2026 guidance for revenue of $3.57 to $3.60 billion, implying 4% to 5% reported growth and 1% to 2% organic growth, and non-GAAP EPS of $2.10 to $2.15, 15% to 17% above 2025 despite an approximately 8% foreign exchange headwind.
Bruker Corporation announced a regular income payment for holders of its 6.375% Mandatory Convertible Preferred Stock, Series A. The Board declared a quarterly cash dividend of $3.9844 per share.
The dividend was declared on April 28, 2026 and will be paid on June 1, 2026 to shareholders of record as of May 15, 2026.
Bruker Corp executive Mark Munch exercised stock options and sold shares in a planned transaction. He exercised options for 2,000 shares of common stock at $22.19 per share and then sold 2,000 shares at $39.90 per share on the same date.
After these transactions, he directly owns 128,443 shares of Bruker common stock. The sale was carried out under a pre-arranged Rule 10b5-1 trading plan adopted by the reporting person.
BRKR filing reports an intended sale of 2,000 shares of Common Stock on 04/15/2026 via a stock option exercise for cash. The filing also lists prior reported dispositions by Mark R. Munch: 2,000 shares on 03/13/2026 for $70,880 and 2,000 shares on 02/13/2026 for $73,880.
Bruker Corporation is asking stockholders to vote at its virtual 2026 Annual Meeting on May 21, 2026. Investors will elect three Class II directors (Laura A. Francis, John J. Phillips, and Hermann F. Requardt), approve on an advisory basis 2025 executive pay, and ratify PricewaterhouseCoopers as auditor for 2026.
The company highlights a pay-for-performance program combining salary, annual cash incentives and long‑term equity, with no broad perquisites and a clawback policy. In 2025, revenue reached $3.4365 billion but organic revenue and non‑GAAP margins declined, reducing incentive payouts. The proxy also details board structure, committee roles, director compensation and significant share ownership, including CEO Frank Laukien’s 26.6% stake.
BRUKER CORP director Bernard Thierry has filed a Form 3 as a reporting person for the company’s stock. The filing shows no reported transactions, with all buy, sell, acquire, and dispose counts and share amounts listed as zero in the transaction summary.
Bruker Corporation announced that Falko Busse, Ph.D., an executive officer and President of the Bruker BioSpin Group, will transition his duties on or around May 1, 2026, with his employment ending on October 31, 2026.
Under a mutual separation agreement with Bruker Switzerland AG, Dr. Busse will receive separation benefits, including severance, a pro-rated bonus, and unused vacation payout totaling an amount in Swiss francs approximately equal to $1,020,351, payable on the separation date. Any unvested equity awards held on that date will be forfeited. The agreement also includes customary restrictive covenants and confidentiality, non-solicitation, and non-disparagement obligations.